Related Experiment Video

Updated: Feb 20, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K

Demodex as a Delivery Vector for Topical Targeted Medications in the Skin for Early Melanoma and Non-Melanoma Skin

Stephen L Strobel1

  • 1Department of Pathology, St Vincent Mercy Medical Ctr, Toledo, OH, USA stephen_strobel@mhsnr.org.

Annals of Clinical and Laboratory Science
|October 26, 2017
PubMed

Insights

Demodex mites show potential as delivery vectors for skin cancer medications. This approach could target early-stage skin cancers, offering a novel therapeutic strategy.

Area of Science:

  • Dermatology
  • Parasitology
  • Oncology

Background:

  • Demodex mites are microscopic arachnids commonly found on human skin.
  • Current treatments for early skin cancer have limitations.
  • Targeted drug delivery remains a challenge in oncology.

Purpose of the Study:

  • To explore the feasibility of using Demodex mites as natural vectors for delivering cytotoxic drugs.
  • To investigate the potential of this method for treating early-stage skin cancer.
  • To discuss the advantages and drawbacks of this innovative approach.

Main Methods:

  • Conceptualization of Demodex mites as drug delivery vehicles.
  • Review of existing literature on Demodex mites and skin cancer therapies.
  • Analysis of potential benefits and limitations.

Main Results:

  • Demodex mites possess characteristics suitable for carrying and delivering therapeutic agents.
  • The proposed method offers a potential route for targeted drug delivery to skin cancer cells.
  • Challenges include mite control, drug loading, and immune response.

Conclusions:

  • Demodex mites represent a novel, albeit preliminary, concept for targeted cancer therapy delivery.
  • Further research is required to validate the proof of concept and address practical limitations.
  • This strategy could potentially enhance treatment efficacy and reduce side effects for early skin cancers.

More Related Videos

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.9K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.2K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
29
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
43
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
31
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K